Who is sponsoring NCT07590336?

NCT07590336 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT07590336?

Interventions in NCT07590336: 68Ga-NYM207 PET/CT.

What condition does NCT07590336 study?

NCT07590336 studies Hepatocellular Carcinoma (HCC).

Is NCT07590336 still recruiting?

NCT07590336 is currently not yet recruiting.

Last reviewed 2026-06-09 · How we verify

NCT07590336

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma

Not yet recruiting Phase 1, PHASE2

What this trial tests

Phase 1, PHASE2 trial testing 68Ga-NYM207 PET/CT in Hepatocellular Carcinoma (HCC) in 100 participants. Not yet recruiting.

Timeline

1 June 2026

1 June 2027

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Enrollment	100
Start date	1 June 2026
Estimated completion	1 June 2027

Drugs / interventions tested

68Ga-NYM207 PET/CT

Conditions studied

Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →

Sponsor

Peking Union Medical College Hospital

Who can join

Eligibility, any sex, with Hepatocellular Carcinoma (HCC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
NCT07406308 — A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07590336 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07590336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing